S-A. Im

1.8k citations

85 papers · 1.1k indexed · h-index 18

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
Cancer Research top 10%
- Breast Cancer Treatment Studies

Papers in ⓘ

Oncology 74
- Cancer Treatment and Pharmacology 39
- HER2/EGFR in Cancer Research 37
- Cancer Immunotherapy and Biomarkers 13
- PARP inhibition in cancer therapy 10
Pulmonary and Respiratory Medicine 59
- Advanced Breast Cancer Therapies 50
- Brain Metastases and Treatment 5

Co-authors: Y-J. Bang (5 shared papers)S-B. Kim (15 shared papers)Tae‐Yop Kim (7 shared papers)Won Ho Kim (1 shared paper)Paul R. Gavine (1 shared paper)Hyoung‐Pyo Kim (1 shared paper)Shethah Morgan (1 shared paper)Chris Womack (1 shared paper)
Journals: Annals of Oncology (45 papers)Cancer Research (23 papers)ESMO Open (10 papers)British Journal of Cancer (4 papers)Oncogene (1 paper)
Partner nations: South Korea United States Spain

In The Last Decade

S-A. Im

78 papers receiving 1.1k citations

Peers

Countries citing papers authored by S-A. Im

Since Specialization

Citations

This map shows the geographic impact of S-A. Im's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S-A. Im with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S-A. Im more than expected).

Fields of papers citing papers by S-A. Im

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S-A. Im. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S-A. Im. The network helps show where S-A. Im may publish in the future.

Co-authors

The 25 scholars most cited alongside S-A. Im, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S-A. Im Line = papers co-authored together S-A. Im links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study British Journal of Cancer ·Xin Su, Ping Zhan, Paul R. Gavine, Shethah Morgan, Chris Womack, X. Ni, Danhong Shen, Y-J. Bang, S-A. Im, Won Ho Kim, E-J Jung, Heike I. Grabsch, Elaine Kilgour	2014	148
2	Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer British Journal of Cancer ·Heon‐Jeong Lee, An Na Seo, Eunice Kim, Min Hye Jang, Young Ju Kim, Ji Hyung Kim, Seong‐Woo Kim, Hee‐Sug Ryu, In Ae Park, S-A. Im, Gyungyub Gong, Kyung Hae Jung, H J Kim, So Yeon Park	2014	112
3	Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer Oncogene ·Hyoung‐Pyo Kim, S-W Han, SH Song, E-G Jeong, M-Y Lee, Daehee Hwang, S-A. Im, Y-J. Bang, Tae‐Yop Kim	2013	98
4	Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028 Cancer Research ·HS Rugo, J.P. Delord, S-A. Im, P.A. Ott, SA Piha-Paul, PL Bedard, Jasgit C. Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andréa Varga, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan	2016	77
5	LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study Annals of Oncology ·Javier Cortés, S-B. Kim, W-P. Chung, S-A. Im, Y.H. Park, Roberto Hegg, Minjung Kim, L-M Tseng, Vanessa Petry, C-F. Chung, Hiroji Iwata, E.P. Hamilton, Giuseppe Curigliano, Binghe Xu, C. Lee, Y. Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz	2021	73
6	LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours Annals of Oncology ·Zarnie Lwin, Carlos Gomez‐Roca, Esma Saâda-Bouzid, (unknown), Federico Longo Muñoz, S-A. Im, Eduardo Castañón, Hélène Senellart, Donna M. Graham, Martin H. Voss, Mark Doherty, Juanita Lopez, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Hyun Cheol Chung	2020	59
7	Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC) Cancer Research ·LA Emens, Francisco J. Esteva, M Beresford, Cristina Saura, Michelino De Laurentiis, S-B. Kim, S-A. Im, Monika Patre, Yibin Wang, Aruna Mani, Hui Liu, Sanne de Haas, Sherene Loi	2019	40
8	LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC Annals of Oncology ·Javier Cortés, David W. Cescon, Hope S. Rugo, S-A. Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, J. M. Perez-Garcia, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gökmen, Sherene Loi, Zhikun Guo, Xuan Zhou, Vassiliki Karantza, W. Pan, Peter Schmid	2021	37
9	Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF British Journal of Cancer ·S-A. Im, J-S Kim, Candelaria Gomez‐Manzano, Juàn Fueyo, T-J Liu, M. S. Cho, C-M Seong, S N Lee, Y K Hong, W. K. Alfred Yung	2001	35
10	Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer British journal of surgery ·Hyo Seop Ahn, Sang‐Ho Jeong, Y G Son, HJ Lee, S-A. Im, Y-J. Bang, HH Kim, H-K Yang	2014	32
11	LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial Annals of Oncology ·Aditya Bardia, Komal Jhaveri, S-A. Im, Sònia Pernas, Michelino De Laurentiis, S. Wang, Noelia Martínez-Jáñez, Giuliano Santos Borges, David W. Cescon, Masaya Hattori, Yen‐Shen Lu, Erika Hamilton, Qilong Zhang, Junji Tsurutani, Kevin Kalinsky, Linhong Xu, Neelima Denduluri, Hope S. Rugo, Binghe Xu, Barbara Pistilli	2023	30
12	376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study Annals of Oncology ·Shanu Modi, William Jacot, Hiroji Iwata, Y.H. Park, María Vidal, Wei Li, Junji Tsurutani, Khalil Zaman, Naoto T. Ueno, Aleix Prat, Konstantinos Papazisis, H. S. Rugo, Nadia Harbeck, S-A. Im, Michelino De Laurentiis, Cecilia Orbegoso, Lotus Yung, F-C. Cheng, Yun Cheng, David Cameron	2023	28
13	Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) Cancer Research ·Masakazu Toi, SJ Lee, Eun‐So Lee, Shoichiro Ohtani, Y-H Im, S-A. Im, Byeong‐Woo Park, S-B. Kim, Y. Yanagita, Shintaro Takao, Shigeo Ohno, K. Aogi, Hiroji Iwata, A Kim, Hironobu Sasano, Isao Yokota, Yasuo Ohashi, Norikazu Masuda	2016	25
14	377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03 Annals of Oncology ·S.A. Hurvitz, Shanu Modi, Wěi Li, Y.H. Park, Wei‐Pang Chung, S-B. Kim, Javier Cortés, Toshinari Yamashita, José Luiz Pedrini, S-A. Im, L-M Tseng, Nadia Harbeck, I. Krop, G. Curigliano, E. Mathias, Jillian Cathcart, A. Cagnazzo, Shahid Ashfaque, Anton Egorov, Fabrice André	2023	24
15	LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study Annals of Oncology ·Peter Schmid, Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Carsten Denkert, Y.H. Park, Rina Hui, N. Harbeck, M. Takahashi, Theodoros Foukakis, M.A. Mouret Reynier, M.I.R. Ferreira, S-A. Im, Fátima Cardoso, Yu Ding, W. Pan, Konstantinos Tryfonidis, Joyce O’Shaughnessy	2023	20
16	Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives British Journal of Cancer ·J. W. Kim, S. J. Kim, Y-H Chung, J-H Kwon, H-J Lee, Y-J Chung, Yoon Jun Kim, Do‐Youn Oh, Seng Hua Lee, Dongwook Kim, S-A. Im, Tae‐Yop Kim, Dae Seog Heo, Y-J. Bang	2008	20
17	Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial Cancer Research ·Debu Tripathy, Joohyuk Sohn, S-A. Im, Marco Colleoni, Fábio Franke, Aditya Bardia, Nadia Harbeck, SA Hurvitz, Louis W.C. Chow, KS Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Keun‐Hwa Jung, Grant W. Carlson, Gareth Hughes, Iván Díaz-Padilla, Caroline Germa, Samit Hirawat, Yen‐Shen Lu	2018	20
18	Abstract P2-09-10: Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study Cancer Research ·RS Finn, Y Liu, M. Martín, HS Rugo, Véronique Dièras, S-A. Im, Karen A. Gelmon, Nadia Harbeck, Zhou Zhu, Dongrui R. Lu, Eric Gauthier, CH Bartlett, DJ Slamon	2018	17
19	181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC) ESMO Open ·Peter Schmid, Sherene Loi, Luis de la Cruz‐Merino, R. Yerushalmi, S-A. Im, A. Sonnenblick, Maria Martinez‐García, Irene Moreno Candilejo, Liam Kennedy, Kristin Griffiths, Richard B. Schwab, Fiona Young, Linchuan Liao, Kelly DuPree, S-B. Kim	2024	16
20	Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) Cancer Research ·S. M. Domchek, Sophie Postel‐Vinay, S-A. Im, Winnie Yeo, J.P. Delord, Antoîne Italiano, Jérôme Alexandre, Benoît You, Susan E.P. Bastian, MG Krebs, Saiama N. Waqar, Mark C. Lanasa, HK Angell, Minhong Tang, Christopher Gresty, Laura L.M. Opincar, Pia Herbolsheimer, Bella Kaufman	2019	16

About S-A. Im

S-A. Im is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 85 papers that have together received 1.1k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (50 papers), Cancer Treatment and Pharmacology (39 papers), HER2/EGFR in Cancer Research (37 papers), Breast Cancer Treatment Studies (18 papers), Cancer Immunotherapy and Biomarkers (13 papers), PARP inhibition in cancer therapy (10 papers), BRCA gene mutations in cancer (5 papers) and Brain Metastases and Treatment (5 papers). The work is most often cited by research in Oncology (799 citations), Cancer Research (242 citations), Pulmonary and Respiratory Medicine (454 citations), Gastroenterology (51 citations) and Genetics (86 citations). S-A. Im has collaborated with scholars based in South Korea, United States and Spain. Frequent co-authors include Y-J. Bang, S-B. Kim, Tae‐Yop Kim, Won Ho Kim, Paul R. Gavine, Hyoung‐Pyo Kim, Shethah Morgan, Chris Womack, Heike I. Grabsch and Daehee Hwang. Their work appears in journals such as Annals of Oncology, Cancer Research, ESMO Open, British Journal of Cancer and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact